Development and validation of a disease-specific quality of life measure QLICD-HY (V2.0) for patients with hypertension

Sci Rep. 2023 Aug 9;13(1):12935. doi: 10.1038/s41598-023-39802-2.

Abstract

The purpose of the present study is to develop and validate the hypertension scale of the Quality of Life Instruments (QoL) for Chronic Diseases system, QLICD-HY (V2.0). The QLICD-HY (V2.0) was developed via a programmed decision method with several focus groups, nominal discussions and pilot testing. The data was collected from 370 hypertensive inpatients and measured their QoL three times before and after treatment. Using correlation, factor analyses, as well as t-tests, the psychometric properties of the scale were assessed with regard to validity, reliability and responsiveness. Correlation and factor analysis supported good construct validity and criterion-related validity when using Short Form 36 as a criterion. Test-retest reliability coefficients for the overall scale score and all domains, with the exception of the psychological and social domain (0.77, 0.78), were greater than 0.80, with a range of 0.77-0.92. The internal consistency for all domains was higher than 0.70. With the exception of the psychological domain and social domain, the overall score and scores for the majority of aspects within each domain underwent statistically significant changes (t-tests) after the treatment. The QLICD-HY (V2.0) has good validity, reliability and responsiveness and can be used as a QoL measure for hypertensive patients.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Humans
  • Hypertension* / diagnosis
  • Psychometrics / methods
  • Quality of Life* / psychology
  • Reproducibility of Results
  • Surveys and Questionnaires